RNA-Based Treatment of Diabetic Retinopathy
By targeting specific regulatory RNAs in diabetic retinopathy, i-RNA's treatment is more specific, and is less prone to drug resistance.
Intravitreal Injection
Eye Drop
i-RNA's patented diabetic retinopathy treatment is potentially longer-lasting and more effective than existing anti-VEGF treatments.
i-RNA's patented diabetic retinopathy treatment is the first in its class to forgo invasive frequent injections, and is potentially more effective than existing treatments.
RNA-based early detection kit for diabetic retinopathy.
With i-RNA's patented panel of RNA biomarkers, we can detect diabetic retinopathy years before current standards.
By analyzing circulating levels of specific RNA biomarkers, we can generate a retinal health assessment score, with which we can detect diabetic retinopathy and stage its progression. Using the retinal health score, we will also be able to provide individualized recommendations for improving your ocular health.
Recent Publications
S. Biswas, B. Feng, S. Chen, J. Liu, E. Aref-Eshghi, J. Gonder, V. Ngo, B. Sadikovic, S. Chakrabarti; The Long Non-Coding RNA HOTAIR Is a Critical Epigenetic Mediator of Angiogenesis in Diabetic Retinopathy. Invest. Ophthalmol. Vis. Sci. 2021;62(3):20. https://doi.org/10.1167/iovs.62.3.20.
S. Biswas, A. Coyle, S. Chen, M. Gostimir, J. Gonder, S. Chakrabarti; Expressions of Serum lncRNAs in Diabetic Retinopathy - A Potential Diagnostic Tool. Front. Endocrinol. 2022;13. https://doi.org/10.3389/fendo.2022.851967.